BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Trading 4.9% Higher – What’s Next?

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT)’s share price traded up 4.9% on Tuesday . The stock traded as high as $9.30 and last traded at $9.22. 133,955 shares changed hands during trading, a decline of 59% from the average session volume of 325,945 shares. The stock had previously closed at $8.79.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on BBOT. Weiss Ratings started coverage on shares of BridgeBio Oncology Therapeutics in a report on Wednesday, January 14th. They issued a “sell (d+)” rating for the company. Raymond James Financial upgraded shares of BridgeBio Oncology Therapeutics to a “moderate buy” rating in a research report on Friday, January 9th. HC Wainwright boosted their price objective on shares of BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the stock a “buy” rating in a research report on Friday, March 6th. Finally, Stifel Nicolaus started coverage on shares of BridgeBio Oncology Therapeutics in a research report on Tuesday, February 10th. They issued a “buy” rating and a $23.00 price objective for the company. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $26.00.

BridgeBio Oncology Therapeutics Trading Up 4.3%

The stock has a 50-day moving average of $9.27. The company has a market cap of $673.73 million, a PE ratio of -5.53 and a beta of 0.51.

Hedge Funds Weigh In On BridgeBio Oncology Therapeutics

Several large investors have recently bought and sold shares of the business. CIBC Private Wealth Group LLC acquired a new position in BridgeBio Oncology Therapeutics in the fourth quarter valued at approximately $63,000. XTX Topco Ltd lifted its holdings in BridgeBio Oncology Therapeutics by 22.4% in the fourth quarter. XTX Topco Ltd now owns 28,633 shares of the company’s stock valued at $358,000 after buying an additional 5,249 shares during the period. Persistent Asset Partners Ltd acquired a new position in BridgeBio Oncology Therapeutics in the fourth quarter valued at approximately $107,000. Squarepoint Ops LLC acquired a new position in BridgeBio Oncology Therapeutics in the fourth quarter valued at about $144,000. Finally, Quadrature Capital Ltd acquired a new position in BridgeBio Oncology Therapeutics in the fourth quarter valued at about $162,000. 54.89% of the stock is currently owned by institutional investors and hedge funds.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.